Changes in HLA Antigens Is Not a Major Mechanism of Acute Myeloid Leukemia Relapse After Matched Allogeneic Stem Cell Transplantation  by Hamdi, Amir et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S116We analyzed IR at day þ28 in patients receiving 2 step
myeloablative haploidentical HSCT. All patients received 12
Gy of total body irradiation followed by 2 x 108 CD3þ cells/kg
donor T cells (HSCT step 1). CY 60 mg/kg/d x 2 was given
starting 2 or 3 days after the T cell infusion in the low and
high risk groups respectively. Tacrolimus and MMF were
begun on day -1. A CD 34 selected product was infused on
day 0 (HSCT step 2) with median CD34 doses of 5.8 and 5.2 x
106/kg in the low and high-risk groups respectively.
19 patients with AML (9), ALL (7), MDS (1), and NHL (2)
without disease, and 16 patients with AML (10), ALL (2), MDS
(3), and T cell NHL (1) with active disease at HSCT were
analyzed. A 17th patient in the high risk group died prior to
engraftment and was not fully evaluable. Outcomes for the
low and high risk groups respectively with 2-24 months
follow-up (median of 9 in each group) were: no rejections;
ANC >500: 11 versus 12 days; grades III-IV GVHD: 5.2%
versus 18.7%; mortality from GVHD 0% versus 6.2%; infec-
tious mortality: 0% versus 12.5%; non-infectious regimen-
related mortality: 0% versus 11.7%; mortality from relapse;
5.2% versus 18.7%; Overall survival: 94.8% versus 52.9%. By
day þ28, all patients had achieved CR and >95% donor
marrow chimerism. Compared to our experience with T cell
depleted (TCD) HSCT, improved T and NK cell IR was
observed, although the low risk group had higher median
numbers of T cells. Conversely, higher numbers of CD56bright
NK cells were present in the high risk group.
Compared to TCD approaches at our institution and
others, the 2 step approach allows for stronger early IR with
low infectious mortality in patients without and with active
malignancy at HSCT. IR was more robust in patients without
active disease. IR in the higher risk groupmay be hindered by
less hospitable marrow stroma and a greater baseline
inﬂammation related to the active malignancy and exacer-
bated by the HSCT. The increased rate of signiﬁcant GVHD
and the prominence of NKbright cells, which are strong
producers of cytokines, may reﬂect this higher state of
inﬂammation. In addition, differences in the degree of T cell
eradication by CY, based on T cell responses to malignancy or
the longer period of T cell activation in the high risk regimen,
may account for variations in IR between the groups.
Recognition of the differences in early IR amongst speciﬁc
patient populations may help optimize post HSCT care.
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Disease relapse after allogeneic hematopoietic stem cell
transplantation (HSCT) is the most important cause of
treatment failure. The mechanisms of leukemia relapse after
allogeneic stem cell transplantation remain elusive. Loss of
HLA class I antigens has been associatedwith disease relapse,
tumor progression and metastasis in solid tumors and has
been shown to be the direct consequence of selective pres-
sure mediated by T cells. We aimed to detect if changes in
HLA antigens occurs and is responsible for leukemia relapse.
We reviewed patients who relapsed post allogeneic stem
cell transplantation (allo-HSCT) for acute myeloid leukemia
(AML) or myelodysplastic syndrome and conducted post-
transplantation studies that included morphologic exami-
nation of bone marrow and HLA typing. Donor and recipient
blood specimens, which were collected pre-transplant and
post-relapse, were typed at intermediate- and high-resolu-
tion for HLA-A, -B, -C, -DRB1, and -DQB1 loci. A leukemia-
enriched population was isolated from peripheral blood
using a CD3þ/CD19þ depletion technique using MACs (Mil-
tenyi, Auburns CA). HLA typing was performed for all
samples either prospectively prior to transplantation and on
archived samples at the time of relapse by polymerase chain
reaction (PCR) ampliﬁcation and oligonucleotide hybridiza-
tion using molecular methods. We compared pre-transplant
and post-relapse specimens with the specimen at diagnosis
to evaluate the loss of heterozygosity (LOH) in blasts.
We identiﬁed 71 patients (median age: 51, 18-67; 48%
male)who relapsed after allo-HSCTand had samples stored at
the time of relapse. Sixty one (86%) transplantations were
matched for 10/10 HLA alleles and 10 (14%) for 9/10 alleles.
Eleven patients (15%) underwent transplantation in ﬁrst
remission (CR1), 15 (21%) in CR2, and 45 (63%) patients had
relapsed AML or primary induction failure. Conditioning
regimen consisted of a myeloablative regimen in 46 patients
(65%) and reduce intensity regimen in 25 patients (35%). The
source of stem-cells was peripheral blood in 47 (66%) and
bone marrow in 24 (34%). LOH in relapsed blasts was pre-
sented inonlyonecaseafterHSCT; in thispatientLOHwasalso
observed in the blasts collected in a pre-transplant specimen.
In conclusion, contrasting with the frequent ﬁnding of
LOH in relapse blasts after HSCT in haploidentical trans-
plantation followed by donor T-cell infusion, LOH in relapse
blasts is not common in T cell-replete matched HSCT. LOH
does not appear to be a dominant escape mechanism for
relapse in allogeneic HSCTwith a closely HLAmatched donor.15
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Although non-myelaoblative conditioning regimens have
proven successful in obtaining engraftment and reducing the
toxicity of allogeneic transplant, improvements are still
needed to improve engraftment rates as well as limit the
incidence of graft versus host disease. Methods to improve
engraftment without added toxicity are especially desirable
in the non malignant setting. Agonists of the Gs-coupled
